Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 26

1.

The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml.

Arribas JR, Horban A, Gerstoft J, Fätkenheuer G, Nelson M, Clumeck N, Pulido F, Hill A, van Delft Y, Stark T, Moecklinghoff C.

AIDS. 2010 Jan 16;24(2):223-30. doi: 10.1097/QAD.0b013e3283348944.

PMID:
20010070
3.

Pharmacokinetics, efficacy, and safety of darunavir/ritonavir 800/100 mg once-daily in treatment-naïve and -experienced patients.

Boffito M, Miralles D, Hill A.

HIV Clin Trials. 2008 Nov-Dec;9(6):418-27. doi: 10.1310/hct0906-418. Review. Erratum in: HIV Clin Trials. 2009 Mar-Apr;10(2):vi. Dosage error in published abstract; MEDLINE/PubMed abstract corrected.

PMID:
19203907
4.

Time to HIV-1 RNA suppression below 5 copies/ml during first-line protease inhibitor-based antiretroviral treatment - any impact of residual viremia on treatment success?

Ripamonti D, Hill A, Lauthouwers E, van Delft Y, Moecklinghoff C.

AIDS Rev. 2013 Oct-Dec;15(4):230-6. Review.

PMID:
24322383
5.

Novel antiretroviral combinations in treatment-experienced patients with HIV infection: rationale and results.

Taiwo B, Murphy RL, Katlama C.

Drugs. 2010 Sep 10;70(13):1629-42. doi: 10.2165/11538020-000000000-00000. Review.

PMID:
20731472
6.

Darunavir: an effective protease inhibitor for HIV-infected patients.

Phung BC, Yeni P.

Expert Rev Anti Infect Ther. 2011 Jun;9(6):631-43. doi: 10.1586/eri.11.48. Review.

PMID:
21692667
7.

Central nervous system penetration and effectiveness of darunavir/ritonavir monotherapy.

Pérez Valero I, González-Baeza A, Montes Ramírez ML.

AIDS Rev. 2014 Apr-Jun;16(2):101-8. Review.

PMID:
24937204
8.

A review of economic evaluations of darunavir boosted by low-dose ritonavir in treatment-experienced persons living with HIV infection.

Mauskopf J, Annemans L, Hill AM, Smets E.

Pharmacoeconomics. 2010;28 Suppl 1:1-16. doi: 10.2165/11587410-000000000-00000. Review.

PMID:
21182340
9.

Protease inhibitor monotherapy as maintenance regimen in patients with HIV infection.

Calza L, Manfredi R.

Curr HIV Res. 2012 Dec;10(8):661-72. Review.

PMID:
23016538
10.

Is there a higher risk of CNS adverse events for PI monotherapy versus triple therapy? A review of results from randomized clinical trials.

Powderly W, Hill A, Moecklinghoff C.

HIV Clin Trials. 2014 May-Jun;15(3):79-86. doi: 10.1310/hct1503-79. Review.

PMID:
24947531
11.

Efficacy and safety of atazanavir/ritonavir-based antiretroviral therapy for HIV-1 infected subjects: a systematic review and meta-analysis.

Menshawy A, Ismail A, Abushouk AI, Ahmed H, Menshawy E, Elmaraezy A, Gadelkarim M, Abdel-Maboud M, Attia A, Negida A.

Arch Virol. 2017 Aug;162(8):2181-2190. doi: 10.1007/s00705-017-3346-9. Epub 2017 Mar 30. Review.

PMID:
28361290
12.

Boosted protease inhibitor monotherapy. What have we learnt after seven years of research?

Pulido F, Matarranz M, Rodríguez-Rivera V, Fiorante S, Hernando A.

AIDS Rev. 2010 Jul-Sep;12(3):127-34. Review.

PMID:
20842201
13.

Protease inhibitor monotherapy.

Pérez-Valero I, Arribas JR.

Curr Opin Infect Dis. 2011 Feb;24(1):7-11. doi: 10.1097/QCO.0b013e3283422cdf. Review.

PMID:
21150592
14.

Darunavir: in treatment-experienced pediatric patients with HIV-1 infection.

McKeage K, Scott LJ.

Paediatr Drugs. 2010 Apr 1;12(2):123-31. doi: 10.2165/11204530-000000000-00000. Review.

PMID:
20218748
15.

Interpretation of resistance data from randomized trials of first-line antiretroviral treatment.

Clotet B, Hill A, van Delft Y, Gupta RK, Moecklinghoff C.

AIDS Rev. 2012 Oct-Dec;14(4):247-55. Review.

PMID:
23258299
16.

Effects of switching to protease inhibitor monotherapy on nucleoside analogue-related adverse events.

Clumeck N, Hill A, Moecklinghoff C.

AIDS Rev. 2014 Oct-Dec;16(4):236-45. Review.

PMID:
25350532
17.

From TMC114 to darunavir: five years of data on efficacy.

Llibre JM, Imaz A, Clotet B.

AIDS Rev. 2013 Apr-Jun;15(2):112-21. Review.

PMID:
23708741
18.

Impact of hepatitis C co-infection on response to antiretroviral treatment.

Pulido F, Hill A, van Delft Y, Moecklinghoff C.

AIDS Rev. 2012 Apr-Jun;14(2):124-31. Review.

PMID:
22627608
19.

Pharmacoeconomics of darunavir.

Fullerton DS, Smets E, De La Rosa G, Mrus JM.

Expert Rev Pharmacoecon Outcomes Res. 2011 Feb;11(1):27-39. doi: 10.1586/erp.10.88. Review.

PMID:
21351854
20.

Efficacy and safety of contemporary dual-drug antiretroviral regimens as first-line treatment or as a simplification strategy: a systematic review and meta-analysis.

Achhra AC, Mwasakifwa G, Amin J, Boyd MA.

Lancet HIV. 2016 Aug;3(8):e351-e360. doi: 10.1016/S2352-3018(16)30015-7. Epub 2016 May 31. Review.

PMID:
27470027

Supplemental Content

Support Center